Codexis Reports Second Quarter 2025 Financial Results

Did the company provide guidance for Q3 and full‑year 2025 revenue and earnings? What was the reported earnings per share (EPS) and how does it compare to analyst expectations? Are there any updates on the company's pipeline or recent product approvals that could drive future growth? How did the revenue beat affect the company's gross margin and operating expenses? What is the current cash position and burn rate, and does the company have enough liquidity to fund its operations and growth initiatives? Did management comment on any macroeconomic or industry trends that could impact future performance? How does Codexis' Q2 performance compare to its main competitors in the biocatalysis space? What was the market reaction to the earnings release in terms of stock price movement and trading volume? Is there any indication of upcoming partnership or licensing deals that could boost revenue streams? What are the key risks highlighted by management that could affect the company's outlook going forward?